Pathology: metastatic/advanced OC (mOC) - 2nd line (L2);
| metastatic/advanced OC (mOC) - 2nd line (L2) | ||||
| JAVELIN ovarian 200 (A vs doxorubicin), 2021 | JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 | NRG GY003, 2020 | ||
| avelumab alone | 1 | T1 | ||
| avelumab plus pegylated liposomal doxorubicin | 1 | T1 | ||
| nivolumab plus ipilimumab | 1 | T1 | ||
| pegylated liposomal doxorubicin | 0 | T0 | T0 | |
| nivolumab alone | 0 | T0 | ||